Furthermore, while tau biomarkers show promise in distinguishing between primary 4R and 3R tauopathies [28], data remain limited regarding their ability to differentiate between specific 4R tauopathies, such as PSP and CBD [28,29]. This evidence concerns the gene MAPT and tauopathy.